Đánh giá tác dụng hỗ trợ điều trị của thực phẩm bảo vệ sức khỏe Saphia Alkali D-REVIE X50 trên người bệnh rối loạn lipid máu có yếu tố nguy cơ tim mạch

Abstract

Objective: To evaluate the efficacy and safety of the health supplement Saphia Alkali D-REVIE X50 (SADX50) in patients with dyslipidemia at cardiovascular risk.

Subjects and methods: A controlled clinical intervention study was conducted on 120 patients with dyslipidemia at Hanoi General Hospital of Traditional Medicine from May 2023 to November 2023, including 60 patients with low and medium cardiovascular risk and 60 patients with high cardiovascular risk. In each group, patients were designated into the study group or control group (30 patients per group), assuring the similarity of age, gender and dyslipidemia levels. In the low and medium cardiovascular risk groups, the study group was administered SADX50 combined with lifestyle changes. In the high cardiovascular risk group, the study group was administered SADX50 combined with Atorvastatin 10 mg/day. Treatment duration was 90 days.

Results: In the low and medium cardiovascular risk groups, after 90 days, the study group showed statistically significant improvements in all serum lipid levels compared to the control group (p<0.05), including Triglyceride, LDL-Cholesterol and HDL-Cholesterol. In the high cardiovascular risk groups, the study group showed a trend of better improvement in lipid levels than the control group, however, this difference was not statistically significant (p>0.05). No severe adverse effects were reported during the study.

Conclusion: SADX50 showed effectiveness and safety in supporting the treatment of dyslipidemia, especially in the group of patients with low and medium cardiovascular risk when combined with lifestyle changes.